BioMarCare, Ariadne Use Grant to Develop Colorectal Cancer Dx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BioMarCare and Ariadne will use a $900,000 grant to develop a protein biomarker-based pharmacogenomic test for predicting which metastatic colorectal cancer patients would respond to treatment.

The companies won the grant from the Binational Industrial Research and Development Foundation (BIRD), said BioMarCare's parent company Hadasit Bio-Holdings, a portfolio of biotech firms based on intellectual property developed and owned by Hadassah University.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.